National HealthCare Corporation (NHC) 주식 분석

회사 개요

National HealthCare Corporation operates within the healthcare sector, specifically focusing on the medical care facilities industry by providing essential services to skilled nursing, assisted and independent living, homecare, hospice, and hospital entities. The company organizes its operations into two primary segments, Inpatient and Homecare and Hospice Services, reflecting a diversified approach to delivering critical patient care across various settings. National HealthCare Corporation holds a market capitalization of $2.76 billion and reported total revenue of $1.52 billion over the trailing twelve months, employing a workforce of 15,278 individuals. These valuation and revenue figures indicate that the company has established itself as a significant player with substantial operational scale, positioning it as a notable entity within the broader healthcare infrastructure landscape.

재무 건전성

National HealthCare Corporation reported a trailing twelve-month revenue of $1.52 billion, generating net income of $120.02 million and an EBITDA of $173.27 million. The gap between the $1.52 billion in revenue and the $120.02 million in net income reveals a cost structure where operating expenses, including cost of goods sold and administrative costs, consume a significant portion of gross receipts before arriving at the bottom line. The company generated $108.38 million in free cash flow, which provides a buffer for capital expenditures, debt repayment, or potential strategic investments, thereby enhancing its financial flexibility. Profitability is reflected across three distinct margins: a gross margin of 39.3%, an operating margin of 8.6%, and a profit margin of 7.9%, indicating that after all operational costs and taxes, the company retains roughly 7.9 cents for every dollar of revenue. On the balance sheet, the company holds $255.80 million in cash against $87.07 million in debt, supported by a debt-to-equity ratio of 8.10, suggesting a leveraged capital structure where equity capital is the primary funding source relative to debt obligations. Liquidity is further supported by a current ratio of 1.82, indicating that current assets are more than double current liabilities, which ensures the ability to meet short-term financial obligations without distress. Furthermore, the return on equity stands at 11.9% while the return on assets is 5.3%, metrics that reveal how effectively management utilizes shareholder capital and total assets to generate profits, with ROE being particularly strong relative to the ROA due to the leverage employed.

밸류에이션 평가

The company trades with a trailing P/E ratio of 23.05 and a forward P/E of 411.19, a stark disparity that implies the market is pricing in significantly higher future earnings growth expectations that are not yet reflected in current performance. The price-to-book ratio is 2.57, indicating that the market values the company at a substantial premium over its book value, likely driven by the intangible value of its healthcare assets and franchise model. Alternative valuation metrics such as a price-to-sales ratio of 1.82 and an EV/EBITDA of 14.92 provide different perspectives, suggesting that the market values the company based on revenue generation and enterprise profitability relative to its cash flows. The stock has traded between a 52-week low of $89.14 and a 52-week high of $177.39, meaning the current trading price sits within this historical range, though the exact current price is not specified in the provided data. The beta of 0.59 indicates that the stock exhibits lower price volatility relative to the broader market, moving less aggressively than the overall index during periods of market fluctuation.

Growth & Income

Revenue growth year-over-year stands at 4.6%, while earnings growth year-over-year is 306.3%, demonstrating that earnings are expanding at a much faster rate than revenue, which often signals one-time gains, margin expansion, or a return to profitability after a period of losses. As a dividend payer, the company offers a dividend yield of 1.4% with a payout ratio of 33.0%, a level that appears sustainable given the high earnings growth and healthy free cash flow generation. The substantial increase in earnings relative to revenue suggests that the current earnings per share figure may be heavily influenced by non-recurring items or a base effect, warranting caution when comparing growth rates directly. Overall, the company presents a profile characterized by robust earnings recovery and moderate revenue expansion, supported by a conservative dividend policy that balances shareholder returns with capital needs for growth.